Details of the Drug Metabolized by Drug-Metabolizing Enzyme (DME)

General Information of Drug (ID: DR3437)
Drug Name
Savolitinib
Synonyms
1313725-88-0; AZD-6094; AZD6094; UNII-2A2DA6857R; CHEMBL3334567; 2A2DA6857R; Savolitinib [INN]; Volitinib(Savolitinib); Savolitinib [USAN:INN]; GTPL9918; SCHEMBL12489208; EX-A845; BDBM50023342; ZINC149738712; AKOS030526403; DB12048; compound 28 [PMID: 25148209]; HY-15959; AS-35250; 1H-1,2,3-Triazolo(4,5-b)pyrazine, 1-((1S)-1-imidazo(1,2-a)pyridin-6-ylethyl)-6-(1-methyl-1H-pyrazol-4-yl)-; KB-333895; FT-0700162; J-690125; 4-{1-[(1S)-1-{imidazo[1,2-a]pyri
Indication Renal cell carcinoma [ICD11: 2C90] Phase 3 [1]
Solid tumour/cancer [ICD11: ICD11: 2A00-2F9Z] Phase 2 [2]
Structure
3D MOL 2D MOL
Pharmaceutical Properties Molecular Weight 345.4 Topological Polar Surface Area 91.6
Heavy Atom Count 26 Rotatable Bond Count 3
Hydrogen Bond Donor Count 0 Hydrogen Bond Acceptor Count 6
Cross-matching ID
PubChem CID
68289010
CAS Number
1313725-88-0
TTD Drug ID
D0LW0T
Formula
C17H15N9
Canonical SMILES
C[C@@H](C1=CN2C=CN=C2C=C1)N3C4=NC(=CN=C4N=N3)C5=CN(N=C5)C
InChI
InChI=1S/C17H15N9/c1-11(12-3-4-15-18-5-6-25(15)10-12)26-17-16(22-23-26)19-8-14(21-17)13-7-20-24(2)9-13/h3-11H,1-2H3/t11-/m0/s1
InChIKey
XYDNMOZJKOGZLS-NSHDSACASA-N
The Metabolic Roadmap of This Drug
The Full List of Drug Metabolites (DM) of This Drug
DM Name DM ID PubChem ID Reaction DM Level REF
Savolitinib Metabolite M17 DM018239 N. A. Unclear - Unclear 1 [3]
Savolitinib Metabolite M2 DM016745
153544886
Unclear - Unclear 1 [3]
Savolitinib Metabolite M3 DM016515
118724484
Unclear - Unclear 1 [3]
Savolitinib Metabolite M38 DM018240 N. A. Unclear - Unclear 1 [3]
Savolitinib Metabolite M5 DM018238 N. A. Unclear - Unclear 1 [3]
Savolitinib Metabolite M17 DM018239 N. A. Unclear - Unclear 2 [3]
Savolitinib Metabolite M44 DM018236 N. A. Unclear - Unclear 2 [3]
Savolitinib Metabolite M8 DM018237 N. A. Unclear - Unclear 2 [3]
The Full List of Metabolic Reaction (MR) of This Drug
MR ID Reactant Product MR Type DME REF
MR010183 Savolitinib Savolitinib Metabolite M3 Unclear - Unclear xdhAC [3]
MR010185 Savolitinib Savolitinib Metabolite M2 Unclear - Unclear CYP1A2 ... [3]
MR010187 Savolitinib Savolitinib Metabolite M5 Unclear - Unclear CYP3A4 [3]
MR010189 Savolitinib Savolitinib Metabolite M17 Unclear - Unclear Unclear [3]
MR010190 Savolitinib Savolitinib Metabolite M38 Unclear - Unclear Unclear [3]
MR010186 Savolitinib Metabolite M2 Savolitinib Metabolite M8 Unclear - Unclear Unclear [3]
MR010184 Savolitinib Metabolite M3 Savolitinib Metabolite M44 Unclear - Unclear Unclear [3]
MR010188 Savolitinib Metabolite M5 Savolitinib Metabolite M17 Unclear - Unclear Unclear [3]
⏷ Show the Full List of 8 MR(s)
References
1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 ClinicalTrials.gov (NCT02127710) A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC). U.S. National Institutes of Health.
3 A Phase 1 Study to Evaluate Absolute Bioavailability and Absorption, Distribution, Metabolism, and Excretion of Savolitinib in Healthy Male Volunteers

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.